Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
about
Primary Progressive Multiple Sclerosis: Putting Together the PuzzleInhibition of Drp1 hyper-activation is protective in animal models of experimental multiple sclerosis.Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Defining Disease Activity and Response to Therapy in MS.Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses.MicroRNAs: Roles in Regulating Neuroinflammation.An update on cladribine for relapsing-remitting multiple sclerosis.Daclizumab for the treatment of multiple sclerosis.Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.B cells and their cytokine activities implications in human diseases.The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders.Modulating inflammation and neuroprotection in multiple sclerosis.Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis.A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.Efficiency of antibody therapy in demyelinating diseases.Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.Melanocortins, Melanocortin Receptors and Multiple Sclerosis.Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics.Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with PrecisionIt's Time For Combination Therapies: in Multiple SclerosisMetabolic pathways as possible therapeutic targets for progressive multiple sclerosis.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?B-cell-targeted therapies in relapsing forms of MS.Imaging outcome measures for progressive multiple sclerosis trialsCytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications.Preventing disability in inflammatory bowel disease.The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome".Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.B Cell Therapy for Multiple Sclerosis: Entering an Era.Regulation and dysregulation of axon infrastructure by myelinating glia.Remyelinating Pharmacotherapies in Multiple Sclerosis.
P2860
Q33365606-5FB7D065-3721-40C1-8654-98E0075D006BQ33833201-DCEE9526-973C-408A-871E-DA7AC3E21E41Q33891255-BDAB4946-B01B-4344-BD4A-877815224C43Q36290143-C6F807CE-9CF2-416D-89B3-E904F3B456DCQ36353053-CF4AE3C7-CF5E-45B7-A121-448AB394CD3DQ36357501-DD95A55D-425A-4D76-BD7D-67E69FBE94F2Q37728642-44B999B8-8F55-4055-98B0-23B31F1805CAQ38287691-1C7A9616-0E3D-4A52-877A-E283CDFAF327Q38600051-529C4525-82D6-4BAA-8E07-33ACEFE3816CQ38604207-F9B48A75-1D78-4FE6-921D-440879B7186AQ38664253-A77F5A66-3401-4E07-A17F-30FD9041FD48Q38665518-9FA43552-1E93-48D9-8DEF-E9CCC049596FQ38665740-E8556A32-43E4-4561-BCB9-BE60DE00B346Q38714054-CFB583F1-06F2-4EC5-8CE5-457F5392B726Q38728373-65F3EF44-E429-4913-9A01-06A5316F8FA8Q38729214-AF8657AF-8579-4095-8CC2-CE430E31C6C8Q38739510-E223A15E-713E-44BB-A8D4-2522C7FA662CQ38747100-C25809A4-0AAA-445A-A27E-35916781B388Q39225440-3D9EA165-508A-4363-BA8A-C7B82F7749F8Q39350409-4F294A76-F396-4B0C-A11F-3964B9E6F129Q39427711-04EE6598-CC39-42F1-8CBE-9042F56C5848Q39458392-6121F0C7-4DBF-4208-9419-60F97F4AE13CQ40045794-7F1AD42F-1B78-4A9C-9F1A-340E52B127BEQ41255081-40D9FDC1-05AE-4D33-AA61-02A903442C2DQ41552761-845E3E80-8F8E-4E8A-B964-0E49A044DA79Q41660408-9DCFDADD-5F5F-435A-850E-9B5A8E79EC09Q41921811-07FBEA4E-D571-4B42-915E-9C1B0355F69EQ42072531-686C79D0-7A84-4FFC-A9A8-0A8016B3FB04Q42360915-F4A7AAF6-7AA8-42E0-8815-8797B30963F8Q42361828-AB7791C8-1F69-41E8-BAF1-22E1AB137A3DQ42372842-90838D60-F10A-4D80-8C56-4885A5A2B4B9Q42631407-C29B094D-A791-4E8A-B3A6-6701324A9359Q42660399-B2C06C33-A589-41A7-8808-24FF1024623AQ45071794-6F639301-CD4A-4ECE-A14B-A628BF9DC951Q45338711-9D73B6AE-D0E7-499E-B7F7-7337ABABC657Q46181413-45475961-2668-43DE-8B8F-BF65D87762B0Q46301560-DFFCDCC3-12C6-4E94-B02D-8166EEA8B4EDQ46583404-E694F68F-BB71-446F-ACD7-F757949B2F21Q46614637-4BA18B3E-11D7-448D-A46B-8B2826095668Q46682011-4CE2954A-84CC-41C2-93F2-6FB03D5E1FBE
P2860
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
@en
type
label
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
@en
prefLabel
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
@en
P2093
P50
P921
P356
P1476
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
@en
P2093
Amit Bar-Or
Annette Sauter
Anthony Traboulsee
Bernhard Hemmer
Donna Masterman
Douglas L Arnold
Fred Lublin
Hideki Garren
Jerry S Wolinsky
Jérôme de Seze
P304
P356
10.1056/NEJMOA1606468
P407
P577
2016-12-21T00:00:00Z